JP2007238598A5 - - Google Patents

Download PDF

Info

Publication number
JP2007238598A5
JP2007238598A5 JP2006307035A JP2006307035A JP2007238598A5 JP 2007238598 A5 JP2007238598 A5 JP 2007238598A5 JP 2006307035 A JP2006307035 A JP 2006307035A JP 2006307035 A JP2006307035 A JP 2006307035A JP 2007238598 A5 JP2007238598 A5 JP 2007238598A5
Authority
JP
Japan
Prior art keywords
stroke
patient
composition
composition according
history
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006307035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007238598A (ja
JP5069448B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2006307035A priority Critical patent/JP5069448B2/ja
Priority claimed from JP2006307035A external-priority patent/JP5069448B2/ja
Publication of JP2007238598A publication Critical patent/JP2007238598A/ja
Publication of JP2007238598A5 publication Critical patent/JP2007238598A5/ja
Application granted granted Critical
Publication of JP5069448B2 publication Critical patent/JP5069448B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2006307035A 2006-02-07 2006-11-13 脳卒中再発予防用組成物 Active JP5069448B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006307035A JP5069448B2 (ja) 2006-02-07 2006-11-13 脳卒中再発予防用組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006029954 2006-02-07
JP2006029954 2006-02-07
JP2006307035A JP5069448B2 (ja) 2006-02-07 2006-11-13 脳卒中再発予防用組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006194043A Division JP4005104B2 (ja) 2006-02-07 2006-07-14 脳卒中再発予防用組成物

Publications (3)

Publication Number Publication Date
JP2007238598A JP2007238598A (ja) 2007-09-20
JP2007238598A5 true JP2007238598A5 (enrdf_load_stackoverflow) 2009-08-20
JP5069448B2 JP5069448B2 (ja) 2012-11-07

Family

ID=38584473

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006307035A Active JP5069448B2 (ja) 2006-02-07 2006-11-13 脳卒中再発予防用組成物

Country Status (1)

Country Link
JP (1) JP5069448B2 (enrdf_load_stackoverflow)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2632967T3 (es) 2008-09-02 2017-09-18 Amarin Pharmaceuticals Ireland Limited Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
PL3278665T3 (pl) 2009-04-29 2021-02-22 Amarin Pharmaceuticals Ireland Limited Stabilna kompozycja farmaceutyczna i sposoby jej zastosowania
EP3563842A1 (en) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
CA3026006C (en) 2009-06-15 2021-09-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
NZ611606A (en) 2010-11-29 2015-10-30 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
DK3815684T3 (da) 2012-06-29 2024-10-21 Amarin Pharmaceuticals Ie Ltd Fremgangsmåder til at reducere risikoen for en kardiovaskulær hændelse i en person i statinbehandling
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10668042B2 (en) 2018-09-24 2020-06-02 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of cardiovascular events in a subject
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent

Similar Documents

Publication Publication Date Title
JP2007238598A5 (enrdf_load_stackoverflow)
ATE510537T1 (de) Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit
JP2012517449A5 (enrdf_load_stackoverflow)
JP2006504795A5 (enrdf_load_stackoverflow)
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
RS54187B1 (en) PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE CONTAINING FUMARIC ACID ESTAR
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
UA110012C2 (uk) Лікарські форми для перорального застосування, що містять ацетат лікарбазепіну
HRP20151202T1 (hr) Oralna formulacija metadoksina
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2009516719A5 (enrdf_load_stackoverflow)
HRP20170734T1 (hr) Povećana biodostupnost lijeka u terapiji naltreksonom
HRP20110497T4 (hr) Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
EP1781277A4 (en) COMBINED COMPOSITION
MX2009004579A (es) Composicion farmaceutica que tiene actividad antisicotica, antidepresiva o antiepileptica, con efecto colateral reducido.
JP2008266291A5 (enrdf_load_stackoverflow)
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
WO2007121545A8 (en) S-nitrosothiols containing compositions for the treatment of fatty liver diseases, obesity and other diseases associated with the metabolic syndrome and the use of such compositions
WO2006062933A3 (en) Stable compositions of fenofibrate with fatty acid esters
JP2006342148A5 (enrdf_load_stackoverflow)
JP2012097034A5 (enrdf_load_stackoverflow)
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon